It has been amply demonstrated that the “incretin effect” is typically reduced or even absent in people with impaired glucose tolerance or diabetes, and this contributes to defective insulin secretion and hyperglycaemia in patients with type 2 diabetes (T2D) [1]. This evidence concerns the gene INS and type 2 diabetes mellitus.